Market Overview

Crispr Therapeutics Falls As Studies Suggest Possible Cancerous Side Effect

Share:
Crispr Therapeutics Falls As Studies Suggest Possible Cancerous Side Effect

Crispr Therapeutics AG (NASDAQ: CRSP) plunged more than 14 percent Monday after Nature Medicine published two studies warning that CRISPR-Cas9 might actually trigger cancer rather than treat targeted diseases.

The research was separately reported by the Karolinska Institute and Novartis AG (ADR) (NYSE: NVS), and Crispr CEO Sam Kulkarni later told STAT News the results were “plausible.”

Why It’s Important

STAT's Sharon Begley called the finding a “potential game-changer” for biotech firms developing CRISPR-reliant therapies, particularly those involving stem cells, cystic fibrosis, combined immunodeficiency and glycogen storage disease.

It also may hinder Crispr as the firm explores new indications.

“It’s something we need to pay attention to, especially as CRISPR expands to more diseases,” Kulkarni said. “We need to do the work and make sure edited cells returned to patients don’t become cancerous.”

The problem — activation of dysfunctional p53 biochemicals meant to repair DNA — might only affect one method of genome-editing, according to STAT.

This means transthyretin amyloidosis candidates by Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) should be safe, as well as Editas Medicine Inc (NASDAQ: EDIT)’s blindness therapy and programs for thalassemia and sickle cell disease.

What’s Next

Additional studies may follow, but in the meantime, Novartis advised therapy developers to ensure genome-edited cells have functional p53 before and after editing, and Karolinska recommended similar monitoring.

Related Links:

More Data Needed On Proteostasis Therapeutics' Cystic Fibrosis Candidate, RBC Says In Downgrade

Abeona Therapeutics Has First-Mover Potential In Rare Diseases, Seaport Says In Bullish Initiation

Posted-In: Nature Medicine Sam KulkarniBiotech News Top Stories Movers Trading Ideas General Best of Benzinga

 

Related Articles (EDIT + CRSP)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

HomeStreet Cost Cuts Should Result In Higher 2019 Earnings, Analyst Says In Upgrade

Baird Defends First Solar As 'Fresh Pick,' Finds Comfort In Revenue Visibility